METABOLIC REGULATORS AND USES THEREOF

• US 20090142336A1
• Filed: 02/23/2007
• Published: 06/04/2009
• Est. Priority Date: 02/28/2006
• Status: Abandoned Application

• Current Assignee: Trustees of Boston University
• Original Assignee: Trustees of Boston University
• Inventors: Ouchi, Noriyuki, Zeng, Ling, Walsh, Kenneth
• Application Number:
  US12/280,961
• Publication Number:
  US 20090142336A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/2221 Relaxins
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 38/45 Transferases (2)
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to metabolic regulators that affect metabolic function, for example metabolic regulators that affect muscle mass, muscle regeneration, muscle hypertrophy, fat mass, insulin and glucose sensitivity, angiogenesis and cardiovascular function. In particular, the present invention relates to modulating metabolic function by administering an effective amount of a pharmaceutical composition comprising an agent, where the agent activates or inhibits the activity and/or gene expression of the metabolic regulator. The metabolic regulators of the present invention are, for example MSP1 (2160028F08Rik; SEQ ID NO: 16); MSP2 (2310043I08Rik; SEQ ID NO: 17); MSP3 (NM_026754;1 110017116Rik; SEQ ID NO: 1); MSP4 (4732466D17Rik; SEQ BD NO: 18); MSP 5 (NM_024237; 1600015H20Rik; SEQ ID NO: 12); Ins16 (AF_156094; SEQ ID NO: 20). The present invention also provides methods to screen for agents that affect the metabolic regulators of the present invention.

Claims

1. A method of modulating a metabolic function in a subject, the method comprising administering to a subject an effective amount of a pharmaceutical composition comprising an agent that affects the activity and/or expression of metabolic regulator, wherein the metabolic regulator is selected from the group of MSP1, MPS2, MPS3, MPS4, MPS5 or Ins16 or homologues thereof, or their expression product or functional fragments thereof, and changing the expression of the metabolic regulator or its level in a cell modulates at least one metabolic function.

2. The method of claim 1, wherein the metabolic function is selected from the group of:

muscle mass, fat mass, angiogenesis, body weight, insulin and/or glucose sensitivity, of combinations thereof.

3. The method of claim 1, wherein the agent is an agonist of MSP1, MPS2, MPS3, MPS4, MPS5 or Ins16.

4. The method of claim 1, wherein the agent is an antagonist of MSP1, MPS2, MPS3, MPS4, MPS5 or Ins16.

5. The method of claim 1, wherein the agent is a small molecule, nucleic acid, nucleic acid analogue, peptide, protein, ribosome, antibody, inhibitory nucleic acid, antisense oligonucleotides, RNAi, shRNA, siRNA, miRNA, and variants and fragments thereof.

6. The method of claims 1 or 3, wherein the agent is the expression product of MSP1, MPS2, MPS3, MPS4, MPS5 or Ins16, or a homologue or variant thereof.

7. The method of claim 4, wherein the antagonist is a small molecule, nucleic acid, nucleic acid analogue, peptide, protein, ribosome, antibody, inhibitory nucleic acid, antisense oligonucleotides, RNAi, shRNA, siRNA, miRNA, and variants and fragments thereof

8. The method of claim 1, wherein the agent is targeted to the muscle.

9. The method of claim 1, wherein the MSP1 is encoded by nucleic acid sequence SEQ ID NO:

16 or a fragment or functional variant or homologue thereof.

10. The method of claim 1, wherein the MSP2 is encoded by nucleic acid sequence SEQ ID NO:

17 or a fragment or functional variant or homologue thereof.

11. The method of claim 1, wherein the MSP3 is encoded by nucleic acid sequence SEQ ID NO:

1 or SEQ ID NO;

2 or a fragment or functional variant or homologue thereof.

12. The method of claim 1, wherein the MSP4 is encoded by nucleic acid sequence SEQ ID NO:

18 or a fragment or functional variant or homologue thereof.

13. The method of claim 1, wherein the MSP5 is encoded by nucleic acid sequence SEQ ID NO:

12 or a fragment or functional variant or homologue thereof.

14. The method of claim 1, wherein the Ins16 is encoded by nucleic acid sequence SEQ ID NO:

20 or a fragment or functional variant or homologue thereof.

15. The method of claim 1, wherein the subject is suffering from a condition or disease selected from a group of:

muscle degeneration, insulin-related disorder, muscle atrophy, obesity or blood vessel loss or combinations thereof.

16. The method of claim 15, wherein the insulin-resistant disorder is non-insulin dependent diabetes mellitus (NIDDM) or insulin-dependent diabetes (IDD) or obesity.

17. The method of claim 1, wherein the subject is suffering from angiogenesis associated with ocular neovascularization, tumor angiogenesis, arthritis, retionopathy, retinopathy of prematurity, age-related macular degeneration, diabetic related retinopathy, psorasis, capillary proliferation in atherosclerotic plaques.

18. The method of claim 1, wherein the metabolic function that is modulated is selected from the group of:

insulin sensitivity and/or glucose sensitivity or body weight or angiogenesis or combinations thereof, and the agent is an agent for MSP3.

19. The method of claim 18, wherein the metabolic function is increased insulin sensitivity and/or increased glucose sensitivity or decreased body weight or increased angiogenesis or combinations thereof, and the agent is an agonist for MSP3.

20. The method of claim 18, wherein the metabolic function is decreased insulin sensitivity and/or decreased glucose sensitivity or increased body weight or decreased angiogenesis or combinations thereof, and the agent is an antagonist for MSP3.

21. The method of claim 1, wherein the metabolic function that is modulated is selected from the group of:

muscle mass, hypertrophy or angiogenesis or combinations thereof, and the agent is an agent for MSP5.

22. The method of claim 21, wherein the metabolic function is increased muscle mass and/or increased hypertrophy and/or increased body weight increased angiogenesis or combinations thereof, and the agent is an agonist for MSP5.

23. The method of claim 21, wherein the metabolic function is decreased muscle mass and/or decreased hypertrophy and/or decreased body weight and/or decreased angiogenesis or combinations thereof, and the agent is an agonist for MSP5.

24. The method of claim 1, wherein the metabolic function that is modulated is selected from the group of:

muscle mass or muscle regeneration or combinations thereof, and the agent is an agent for Ins16.

25. The method of claim 24, wherein the metabolic function is increased muscle mass or increased muscle regeneration or increased weight loss or combinations thereof, and the agent is an agonist for Ins16.

26. The method of claim 24, wherein the metabolic function is decreased muscle mass or decreased muscle regeneration or decreased weight loss or combinations thereof, and the agent is an antagonist for Ins16.

34. The method of claim 1, wherein modulating is an increase in the metabolic function in the subject.

27-33. -33. (canceled)